对呼吸道病原体具有活性的肽脱甲酰酶抑制剂。
Peptide deformylase inhibitors with activity against respiratory tract pathogens.
作者信息
East Stephen P, Beckett R Paul, Brookings Daniel C, Clements John M, Doel Sheila, Keavey Kenneth, Pain Gilles, Smith Helen K, Thomas Wayne, Thompson Alison J, Todd Richard S, Whittaker Mark
机构信息
British Biotech Pharmaceuticals Limited, Watlington Road, Oxford OX4 6LY, UK.
出版信息
Bioorg Med Chem Lett. 2004 Jan 5;14(1):59-62. doi: 10.1016/j.bmcl.2003.10.013.
PMID:14684298
Abstract
A series of analogues of the peptide deformylase (PDF) inhibitor BB-3497 where the P3' amide bond was replaced with a ketone functionality is described. The in vitro antibacterial profiling of these compounds revealed that they demonstrate activity against pathogens associated with respiratory tract infections.
摘要
描述了一系列肽脱甲酰基酶（PDF）抑制剂BB-3497的类似物，其中P3'酰胺键被酮官能团取代。这些化合物的体外抗菌谱显示，它们对与呼吸道感染相关的病原体具有活性。
相似文献
1
Peptide deformylase inhibitors with activity against respiratory tract pathogens.
Bioorg Med Chem Lett. 2004 Jan 5;14(1):59-62. doi: 10.1016/j.bmcl.2003.10.013.
2
Discovery of piperazic acid peptide deformylase inhibitors with in vivo activity for respiratory tract and skin infections.
Bioorg Med Chem Lett. 2019 Aug 15;29(16):2410-2414. doi: 10.1016/j.bmcl.2019.05.028. Epub 2019 May 16.
3
Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods.
J Antimicrob Chemother. 2005 Feb;55(2):200-8. doi: 10.1093/jac/dkh540. Epub 2005 Jan 13.
4
Structures of Staphylococcus aureus peptide deformylase in complex with two classes of new inhibitors.
Acta Crystallogr D Biol Crystallogr. 2012 Jul;68(Pt 7):784-93. doi: 10.1107/S0907444912011912. Epub 2012 Jun 15.
5
6
Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents.
J Med Chem. 2000 Jun 15;43(12):2324-31. doi: 10.1021/jm000018k.
7
In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698.
J Antimicrob Chemother. 2004 Apr;53(4):664-8. doi: 10.1093/jac/dkh129. Epub 2004 Feb 18.
8
In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens.
Eur J Clin Microbiol Infect Dis. 1996 Aug;15(8):696-8. doi: 10.1007/BF01691164.
9
A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
J Chemother. 1998 Aug;10(4):276-9. doi: 10.1179/joc.1998.10.4.276.
10
Evaluation of the in-vitro activity of furopenem (SY5555 or SUN5555) against respiratory tract pathogens and beta-lactamase producing bacteria.
J Antimicrob Chemother. 1995 Apr;35(4):535-9. doi: 10.1093/jac/35.4.535.
引用本文的文献
1
Insights from ligand and structure based methods in virtual screening of selective Ni-peptide deformylase inhibitors.
J Mol Model. 2012 Feb;18(2):693-708. doi: 10.1007/s00894-011-1068-6. Epub 2011 May 12.
2
Comparative QSAR studies on peptide deformylase inhibitors.
J Mol Model. 2007 May;13(5):543-58. doi: 10.1007/s00894-007-0175-x. Epub 2007 Feb 27.
3
Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor.
Antimicrob Agents Chemother. 2004 Dec;48(12):4835-42. doi: 10.1128/AAC.48.12.4835-4842.2004.
Zotero 插件